ERBB2 and lung adenocarcinoma: (60) reported that in patients with lung adenocarcinoma aged 45 years or younger, there was a higher occurrence of genetic alterations in human epidermal growth factor receptor 2 (HER2) and ALK, along with concurrent EGFR/TP53 mutations.